menu
    • menu

    Company profile for Spinogenix

    NEW Drugs in Dev: 3
    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Virtual Booth

    Contact Supplier

    Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    In most neurodegenerative diseases we lose connections - synapses – between neurons, a process that contributes to declines in cognition and motor function that characterize these diseases. At Spinogenix we are developing first-in-class, novel small molecule drugs (SPGs) that restore synapses to improve and potentially restore cognitive and motor function. Our approach is unique for diseases of the central nervous system. S...
    In most neurodegenerative diseases we lose connections - synapses – between neurons, a process that contributes to declines in cognition and motor function that characterize these diseases. At Spinogenix we are developing first-in-class, novel small molecule drugs (SPGs) that restore synapses to improve and potentially restore cognitive and motor function. Our approach is unique for diseases of the central nervous system. Spinogenix is developing a new class of therapeutics to restore memory and motor functions lost in neurodegenerative and psychiatric diseases.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    SpinogenixUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    10210 Campus Point Dr, San Diego, California 9212
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://spinogenix.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/spinogenix/about/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Spinogenix To Showcase Tazbentetol's Neuroprotective Effects
    Spinogenix To Showcase Tazbentetol's Neuroprotective Effects

    03 May 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7262781

    FIRSTWORD PHARMA
    03 May 2026
    Share Share
    Spinogenix Launches Phase 2B/3 Trial Of SPG601 For Fragile X
    Spinogenix Launches Phase 2B/3 Trial Of SPG601 For Fragile X

    23 Apr 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/spinogenix-announces-clarity-a-phase-2b3-trial-of-spg601-for-the-treatment-of-fragile-x-syndrome-302751504.html

    PR NEWSWIRE
    23 Apr 2026
    Share Share
    Spinogenix's SPG601 Proves Effective in Fragile X Study
    Spinogenix's SPG601 Proves Effective in Fragile X Study

    09 Apr 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/new-peer-reviewed-research-demonstrates-neurophysiological-efficacy-of-spinogenixs-spg601-in-patients-with-fragile-x-syndrome-302738063.html

    PR NEWSWIRE
    09 Apr 2026
    Share Share
    Spinogenix Shows Positive Phase 2 Results For Tazbentetol
    Spinogenix Shows Positive Phase 2 Results For Tazbentetol

    26 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/spinogenix-reports-early-improvements-in-phase-2-trial-of-tazbentetol-in-patients-with-schizophrenia-at-the-schizophrenia-international-research-society-sirs-2026-annual-congress-302725950.html

    PR NEWSWIRE
    26 Mar 2026
    Share Share
    Spinogenix Wraps Phase 2 Trial Enrollment For Tazbentetol
    Spinogenix Wraps Phase 2 Trial Enrollment For Tazbentetol

    11 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/spinogenix-completes-enrollment-in-phase-2-clinical-trial-of-tazbentetol-for-schizophrenia-treatment-302710783.html

    PR NEWSWIRE
    11 Mar 2026
    Share Share
    Spinogenix Secures FRAXA Backing For Phase 2B (FXS) Trial
    Spinogenix Secures FRAXA Backing For Phase 2B (FXS) Trial

    02 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/spinogenix-announces-fraxa-research-foundation-support-for-pis-leading-phase-2b-trial-of-investigational-therapy-spg601-for-people-with-fragile-x-syndrome-fxs-302700820.html

    PR NEWSWIRE
    02 Mar 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search